• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    "LIOPHILIZATION METHOD, COMPOSITIONS AND KITS". The present invention relates to a method for lyophilization, in particular, methods for lyophilization of formulations comprising AT III. Also provided are compositions prepared therefrom. Also provided are kits comprising the compositions and / or lyophilized products.
    公开号:BR112012012460B1
    申请号:R112012012460-9
    申请日:2010-11-23
    公开日:2020-06-23
    发明作者:Jianxin Guo；Anthony Klos；Deborah Barnette
    申请人:Grifols Therapeutics Inc.；
    IPC主号:
    专利说明:

    CROSS REFERENCE TO RELATED ORDERS
    [0001] The present application claims the benefit of U. S. No. 61/264. 014, filed on November 24, 2009, which is incorporated herein by reference in its entirety. FIELD OF THE INVENTION
    [0002] The present invention relates to methods for lyophilization of compositions, in particular aqueous pharmaceutical formulations, comprising at least one active ingredient and compositions prepared therefrom, in particular compositions, kits and methods for lyophilizing antithrombin-II (AT III). BACKGROUND OF THE INVENTION
    [0003] Lyophilization is a method commonly used for the preparation of active ingredients in more solid forms of pharmaceutical products. For example, it has been shown that an active ingredient, such as AT III, which is an alpha2-glycoprotein normally present in plasma and is a plasma thrombin inhibitor, has relatively poor stability in solution. Consequently, AT III was processed into lyophilized preparations.
    [0004] It has been proposed that lyophilization reduces or inhibits the degradation of the active ingredient by removing solvent components in a formulation to levels that no longer support chemical reactions or biological growth. Additionally, it is believed that solvent removal reduces molecular mobility, reducing the potential for degradative reaction. Also, it is desirable that crystallization excipients (e.g., amino acids and salts), which are commonly used in lyophilized products, crystallize as completely as possible during freezing in order to provide a solid matrix to support the cake structure. However, a series of previous attempts to lyophilize aqueous pharmaceutical formulations have failed to achieve satisfactory degrees of crystallization. For example, it has been shown that the various freezing and / or annealing steps of a typical lyophilization protocol itself are inefficient in promoting crystallization. In addition, it has been suggested that the presence of certain excipients of crystallization (e.g., alanine and sodium chloride) may inhibit or reduce the crystallization of any excipient, thereby also limiting the extent of crystallization.
    [0005] Although several attempts have been made to lyophilize aqueous pharmaceutical formulations, there remains a need for effective lyophilization methods and compositions prepared therefrom. SUMMARY OF THE INVENTION
    [0006] In one aspect, the present invention provides a method of lyophilizing a composition comprising at least one active ingredient and at least one crystallization excipient. The method comprises: exposing the composition to a first temperature for a first period of time sufficient to obtain a first composition having at least one crystallization excipient partially or completely crystallized.
    [0007] In another aspect, the present invention provides a method of lyophilizing a liquid composition comprising AT III derived from plasma, NaCI and alanine. The method comprises:
    (a) exposing the composition to about 54 ° C or below, so that the temperature of the composition is about 48 ° C or below for about 5 hours or more, so as to provide a first composition having one or more components completely or almost completely crystallized; and (b) drying the first composition to obtain a lyophilized cake.
    [0008] In some respects, the present invention provides compositions including cakes prepared according to the methods disclosed herein.
    [0009] In other respects, the present invention provides a kit comprising one or more of the compositions and / or lyophilized cakes prepared according to the methods disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS
    [00010] Figure 1. Thermogram by DSC during freezing and heating of NaCI solution (0.15M).
    [00011] Figure 2. Thermograms by DSC during freezing (A) and heating (B) of alanine solution (0.1 M).
    [00012] Figure 3. Thermograms by DSC during freezing (A) and heating (B) of reconstituted AT III.
    [00013] Figure 4. The optimal crystallization conditions provided by the DOE analysis.
    [00014] Figure 5. A. Change in thermal capacity (Cp) during freezing and annealing through cycle ETP-5807. B. Change of Cp during the first freeze. C. Alteration of Cp during annealing. D. Change of Cp during the second freeze.
    [00015] Figure 6. Change of thermal flow with temperature through the ETP-5807 cycle. The melting heat for the melting peak was determined to be 5.5 J / g.
    [00016] Figure 7. A. Change of Cp during freezing and annealing by extending the freezing maintenance time to 5 hours. B. Change of Cp during the first freeze. C. Change of Cp during heating rise from -52 ° C to -30 ° C. D. Alteration of Cp during annealing. E. Change of Cp during the second freeze.
    [00017] Figure 8. Change of thermal flow with temperature, by extending the freezing maintenance time from 2 hours to 5 hours. The melting heat for the melting peak was determined to be 6.4 J / g.
    [00018] Figure 9. Lyophilization profile of AT III through the ETP-5807 cycle conducted in the Lyostar II FTS unit.
    [00019] Figure 10. Product temperature data during freezing through the ETP-5807 cycle in an FTS unit.
    [00020] Figure 11. Lyophilization profile of AT III when frozen at -54 ° C for 2 hours.
    [00021] Figure 12. Product temperature data when frozen at -54 ° C for 2 hours.
    [00022] Figure 13. Lyophilization profile of AT III when frozen at -54 ° C for 6 hours in an FTS unit.
    [00023] Figure 14. Product temperature data when frozen at -54 ° C for 6 hours in an FTS unit.
    [00024] Figure 15. Lyophilization profile AT III when frozen at - 50 ° C for 6 hours in an FTS unit.
    [00025] Figure 16. Product temperature data when frozen at -50 ° C for 6 hours in an FTS unit.
    [00026] Figure 17. Lyophilization profile of AT III when frozen at -60 ° C for 6 hours in Usifroid.
    [00027] Figure 18. Product temperature data when AT III frozen at -60 ° C for 6 hours in Usifroid.
    [00028] Figure 19. Lyophilization profile AT III when frozen at - 52 ° C for 15 hours.
    [00029] Figure 20. Product temperature data when frozen at -52 ° C is 15 hours.
    [00030] Figure 21. Micrograph of electronic scanning of cakes (200 x magnification). The scale bars are equal to 100 pm. A: a fragmented cake. B: a solid cake.
    [00031] Figure 22. Scanning electron micrograph of NaCI. 200x magnification on the left and 1500x magnification on the right. The scale bar is equal to 100 prn (A) and 10 pm (B).
    [00032] Figure 23. Scanning micrograph of alanine. 50 x magnification on the left and 200 x magnification on the right. The scale bar is equal to 500 pm (A) and 100 pm (B).
    [00033] Figure 24. X-ray powder diffraction (XRD) patterns using a diffractromer for NaCI, alanine, ETP 5807 (fragmented cake) and material from the second ETP 5807 operation (solid cake). DETAILED DESCRIPTION OF THE INVENTION
    [00034] The present invention provides the unexpected discovery that a single low-temperature freezing step before drying is sufficient to induce crystallization of crystallizable excipients in formulations comprising an active ingredient and, thus, the present methods provide robust excipient crystallization , while also providing a more efficient, practical and / or robust lyophilization protocol. The present methods allow for an increased degree of crystalline bulking agents with respect to previous methods, while maintaining the stability and activity of the active ingredient present in the formulations.
    [00035] In one aspect, the present invention provides a method of lyophilizing a composition comprising at least one active ingredient and at least one crystallization excipient. The method comprises exposing the composition to a first temperature for a first period of time sufficient to obtain a first composition having at least one crystallization excipient partially or completely crystallized.
    [00036] The composition can be a liquid or a semi-solid composition. For example, the composition can be an aqueous pharmaceutical solution or suspension comprising at least one active ingredient and at least one crystalline excipient.
    [00037] In one embodiment, the composition is a liquid formulation, preferably an aqueous solution. In another embodiment, the composition is suitable for pharmaceutical use, for example, a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent.
    [00038] In one embodiment, the composition is a pharmaceutical composition comprising at least one active ingredient, at least one crystalline excipient and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings and the like that are physiologically compatible. The type of vehicle can be selected based on the intended route of administration. In some embodiments, the vehicle is suitable for administration by, but not limited to, intravenous, inhalation, parenteral, subcutaneous, intramuscular, intravenous, intra-articular, intrabronchial, intra-abdominal, intracapsular, intracartilaginous, intracavitary, intracellular, intracerebellar, intracerebroventricular, intracólicos, intracervical, intragástricos, intrahepatic, intramiocár- physicians, intraosteais, intrapélvicos, intrapericardíacos, intraperitoneal, intrapleural, intraprostáticos, intrapulmonary, intra-rectal, intrarenal, intraretinais, intraspinal, intra-synovial, intratorácidos, intra- uterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal or transdermal. Pharmaceutically acceptable vehicles include, but are not limited to, sterile aqueous solutions or dispersions for the preparation of sterile injectable solutions or dispersions. Active ingredient
    [00039] In some embodiments, the at least one active ingredient can be any active ingredient including, but not limited to, proteins, nucleic acids and combinations thereof. Proteins can include, but are not limited to, glycoproteins (eg AT III), clotting factors, growth factors, cytokines, antibodies and chimeric constructs. The term "protein" here is intended to be broad and refers to human or other native or collective native mammalian proteins; and / or homogeneous or heterogeneous distribution of polypeptides arising from a single or multiple gene products; and / or protein fragments showing a particular activity; and / or such proteins and / or active fragments thereof produced by recombinant techniques, including transgenic technology.
    [00040] In some embodiments, the at least one active ingredient is a protein. In one embodiment, the protein is AT III. In other embodiments, the composition comprises only one active ingredient, where the active ingredient is AT III. In another embodiment, AT III is the only active ingredient in the composition, however, the composition comprises other proteins, including non-AT III proteins and / or inactive forms of AT III. For example, functional AT III can be a percentage of the total protein content of the composition.
    [00041] The term "AT III", as used here, is intended to be broad, unless specifically stated otherwise. For example, the term refers to all naturally occurring polymorphs of AT III. The term also includes functional fragments of AT III, chimeric proteins comprising AT III or functional fragments thereof, homologues obtained by analogous substitution of one or more amino acids of AT III and species homologs. The term also refers to all AT III polypeptides that are a product of recombinant DNA technology, including an AT III that is a product of transgenic technology. For example, the gene encoding AT III can be inserted into a mammalian gene encoding a whey protein in such a way that the DNA sequence is expressed in the mammary gland as described, for example, in US Patent No. 5. 322. 775, which is hereby incorporated by reference for its teaching of a method of producing a proteinaceous compound. The term also refers to all AT III proteins chemically synthesized by methods known in the art such as, for example, solid phase peptide synthesis. The term also refers to AT III prepared from plasma. The term also refers to AT III that can be obtained commercially. AT III can correspond to human or non-human AT III.
    [00042] In one embodiment, AT III is plasma derived AT III. In another embodiment, AT III is prepared from a plasma fraction paste. In other embodiments, AT III is prepared from a fraction of plasma without albumin or a fraction of pre-purified AT III preparation. U.S. Patent No. 5,561,115 to Tenold is hereby incorporated by reference for his teaching of a method of preparing AT III from serum or plasma.
    [00043] In other embodiments, AT III is recombinant AT III. The production of recombinant proteins, including recombinant AT III, is described, for example, in U. S. Nos. 4. 517. 294, 4. 632. 981, 4. 873. 316, 5. 420. 252, 5. 618. 713, 5. 700. 663, 5. 843. 705, 6. 441. 145, 6. 878, 813, 7,019, 193, Fan et al. , JBC, 268: 17588 (1993), Garone et al. , Biochemistry, 35: 8881 (1996), International Publication No. W002 / 02793; U. S. Nos. US2003 / 096974 and US2006 / 0024793 and Gillespie et al. , JBC, 266: 3995 (1991), each of which is incorporated herein by reference for its teachings on the production of recombinant proteins, including recombinant AT III.
    [00044] In one embodiment, the composition is characterized as comprising an AT III having a purity of more than 90%. In other embodiments, AT III has a purity greater than 95%, preferably at least about 99%. In some embodiments, at least about 50%, illustratively, about 50% to about 100%, about 60% to about 90%, about 70% to about 80% of all AT III in the composition is AT III active.
    [00045] In other embodiments, the composition to be lyophilized comprises at least about 0.1 mg / ml of AT III, illustratively, about 0.1 to about 100 mg / ml, about 0.5 to about 50 mg / ml, about 1 to about 30 mg / ml and about 5 to about 15 mg / ml of AT III, where AT III is a fraction or all of the protein present in the composition.
    [00046] In one embodiment, the composition comprises a therapeutically effective amount of AT III. A "therapeutically effective amount" refers to an effective amount, in dosages and for periods of time necessary, to obtain the desired therapeutic result such as, for example, anticoagulation associated with hereditary antithrombin deficiency. A therapeutically effective amount of AT III can vary according to factors such as the disease state, age, sex and weight of the individual and the ability of AT III to stimulate a desired response in the individual. A therapeutically effective amount may also be one in which any harmful or toxic effects of AT III are outweighed by the therapeutically beneficial effects.
    [00047] In other embodiments, the composition comprises a prophylactically effective amount of AT III. A "prophylactically effective amount" refers to an effective amount, at the dosages and for periods of time necessary, to obtain the desired prophylactic result such as, for example, preventing or inhibiting thromboembolic episodes in individuals who have had multiple episodes thromboembolic or patients who are at risk for other episodes. A prophylactically effective amount can be determined as described above for the therapeutically effective amount. Crystallization Excipient
    [00048] In one embodiment, at least one crystallization excipient is selected from the group consisting of alanine, mannitol, glycine and NaCI.
    [00049] In some embodiments, at least one crystallization excipient is present in the composition in a total amount of crystallization excipient of at least about 0.01% (weight / v), illustratively, about 0.01% at about 10%, about 0.1% to about 5% and about 0.7% to about 1.8% (weight / v).
    [00050] In other embodiments, the lyophilized product comprises at least about 20% (weight / v) of total crystallization excipient, illustratively, about 20 to about 80%, about 30 to about 70%, and about from 36 to about 60% (weight / v) of total crystallization excipient.
    [00051] In some embodiments, the at least one crystallization excipient is alanine and NaCI. In one embodiment, NaCI is present in an amount of about 50 mM to about 30C mM, preferably about 100 mM to about 250 mM. In one embodiment, sodium chloride itself can be used without any of the aforementioned crystallization excipients, in which case it can be included in the formulation in an amount of about 300 nM or more. In other embodiments, the composition (for example, aqueous pharmaceutical formulation) is a hypertonic solution.
    [00052] In addition to the at least one active ingredient and at least one crystallization excipient, the composition may also further comprise one or more other excipients, that is, one or more other substances used in combination with the active ingredient to constitute the composition. Some non-limiting examples of one or more excipients include stabilizing agents, buffering agents, divalent cations (eg, calcium salts), binders, lubricants, disintegrants, diluents, dyes, flavorings, glidants, surfactants, absorbents and sweetening agents.
    [00053] The combinations of active ingredients and excipients according to the present invention can provide stability of an active ingredient in lyophilized preparations; however, the compositions of the present invention can also exhibit a degree of stability in the liquid or semi-solid state as well.
    [00054] In other embodiments, the composition further comprises a stabilizing agent. For example, the stabilizing agent can be selected from the group consisting of sucrose, mannitol and trehalose. Before lyophilization, the stabilizing agents can be present in the composition in a total amount of stabilizing agent of at least about 1%, illustratively about 1% to about 4% and about 2% to about 3%. In some embodiments, the stabilizing agent is present in the composition in an amount of about 2%.
    [00055] A buffer may also be present in the compositions of the present invention, in particular where the active ingredient is likely to be adversely affected by pH shifts during lyophilization. The pH should preferably be kept in the range of about 6 to 8 during lyophilization and, more preferably, at a pH of about 7. The buffering agent can be any physiologically acceptable chemical entity or combination of chemical entities which have the ability to act as binders including, but not limited to, phosphate buffer, citrate buffer, acetate buffer, citric acid / phosphate buffer, histidine, tris- (hydroxymethyl) -aminomethane (Tris), 1, 3-bis- [tris- (hydroxymethyl) methylamino] -propane (BIS-Tris Propane), piperazine-N, N'-bis- (2-ethanesulfonic) (PIPES), 3- {N- morpholino) propane-sulfonic acid (MOPS), N-2-hydroxyethyl-piperazine-N'-2-ethane-sulfonic acid (HEPES), 2- (N-morpholino) ethane-sulfonic acid (MES) and N-2- acetamido-2-aminoethane sulfonic (ACES).
    [00056] In one embodiment, the buffering agent is included in the composition at a concentration of about 10 to about 50 mM. When histidine is added to the compositions, concentrations of at least about 20 mM, preferably about 25 mM, can be used, alone or in combination with other buffers, such as Tris.
    [00057] In other embodiments, the composition further comprises a divalent cation, for example, a calcium salt. In one embodiment, the calcium salt is present in an amount of about 1 mM to about 5 mM.
    [00058] In one embodiment, the composition still comprises a surfactant. The surfactant can be present in an amount of about 0.1% or less. Non-limiting examples of surfactants include POLYSORBATE 20 (eg TWEEN® 20), POLYSORBATE 80 (eg TWEEN® 80), sorbitan polyoxyethylene fatty acid ester (80), Pluronic polyols (eg F-38, F -68) and dodecyl polyoxyethylene glycol ethers (for example, Brij-35).
    [00059] According to the present invention, the composition can also comprise an antioxidant. The antioxidant can be present in the composition in a total amount of at least 0.05 mg / ml, illustratively, about 0.05 to about 50 mg / ml, about 0.1 to about 10 mg / ml, and about 1 to about 5 mg / ml. Non-limiting examples of antioxidants include N-Acetyl-L-Cysteine / Homocysteine, glutathione, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Tro-lox), lipoic acid, methionine, sodium thiosulfate , platinum, glycine-glycine-histidine (tripeptide) and butylated hydroxytoluene (BHT). In some embodiments, the composition further comprises glutathione in an amount of about 0.05 mg / ml to about 5 mg / ml.
    [00060] The compositions of the present invention may also comprise calcium or another divalent cation, in particular where the cation confers interaction with the active ingredient to maintain its activity. In one embodiment, the composition still comprises a divalent cation. In another embodiment, the divalent cation is provided as a calcium salt, for example, calcium chloride, but it can also be other calcium salts, such as calcium gluconate, calcium glubionate or calcium gluceptate. In some embodiments, the calcium salt is present in an amount of about 1 mM to about 5 mM. In other embodiments, the calcium salt is present in an amount of about 3 mM to about 4 mM, preferably about 4 mM.
    [00061] In some embodiments, the combination of histidine and glutathione can produce synergistically beneficial effects on the stability of a particular active ingredient present in a composition. For example, histidine, while acting as a buffer, can also act as a metal chelator. To the extent that it is believed that the activity level of the active ingredient is affected by metal-induced oxidation, for example, histidine can therefore act to stabilize the bond through oxidation of metal ions. It is believed that, through the binding of these metals, glutathione (or any other antioxidant present) is thus able to confer additional antioxidative protection, once the oxidative effect of the metal ions bound by histidine has been contained. Other chilling agents can also be included in the compositions / formulations of the present invention. Such chelating agents preferably bind to metals, such as copper and iron, with greater affinity than calcium, for example, where a calcium salt is being used in the composition. An example of such a chelator is deferoxamine, which is a chelating agent that facilitates the removal of Al ++ and iron. Lyophilization
    [00062] In general, temperatures and / or temperature ranges specific to a lyophilization method refer to the shelf temperature in the lyophilizer equipment, unless otherwise mentioned. The shelf temperature refers to the control temperature for refrigerant flow through the freeze dryer shelves, which is typically the temperature that controls in terms of temperature during freeze drying. The temperature of the sample (that is, the temperature of the product) depends on the temperature of the shelf, the pressure of the chamber and / or the rate of evaporation / sublimation during primary drying (evaporative cooling makes the product temperatures lower than the temperature of the shelf ). A. Freezing
    [00063] In one embodiment, the first temperature is about -48 ° C or below. In another embodiment, the first temperature is about -54 ° C or below. In other embodiments, the time period is at least about 30 minutes, illustratively, about 30 minutes to about 20 hours, about 1 to about 18 hours, about 2 to about 16 hours, about 3 to about 14 hours, about 4 to about 10 hours, about 5 to about 8 hours, and about 6 to about 7 hours. In one embodiment, the time period is about 6 hours.
    [00064] The temperature and time period may depend on factors such as the volume of the solution per bottle, regardless of the composition to be lyophilized.
    [00065] The present invention sometimes refers to the goal of complete crystallization or 100% excipient and those skilled in the field will understand that "complete crystallization" can be difficult to verify, particularly where the sensitivity of the technology cannot inform , with absolute precision, whether an excipient is completely or 100% crystallized. Therefore, in practical terms, the invention provides freeze-drying methods that at least improve the excipient crystallization over previous methods. Consequently, as used here, "fully crystallized" products can be evaluated, for example, through differential scanning calorimetry (DSC), where those skilled in the field recognize that a non-reversible exothermic event on a first scan represents a crystallization event, which indicates that a crystallization excipient does not crystallize completely during lyophilization. In some embodiments, the at least one crystallization excipient is partially crystallized, in which partly crystallized is characterized as a degree of crystallization of about 50% or more, illustratively, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least at least about 99%, at least about 99.5%, at least about 99.8% and less than 100%. B. Ringing
    [00066] In other embodiments, the method further comprises exposing the first composition to a second temperature for a second period of time to obtain a second composition, in which the second temperature is above the first temperature.
    [00067] In one embodiment, the second temperature is at least about 5 ° C above the first temperature, illustratively, about 5 ° C to about 30 ° C and about 10 ° C to about 20 ° C above first temperature. For example, where the first temperature is about -50 ° C, in some embodiments, the second temperature is about -30 ° C.
    [00068] In some embodiments, the second period of time is at least 10 minutes, illustratively, about 10 minutes to about 10 hours, about 30 minutes to about 8 hours, about 1 hour to about 6 hours, and about 2 hours to about 4 hours. In other embodiments, the second time period is less than, greater than or about equal to the first time period.
    [00069] Without being bound by any particular theory, it is believed that such annealing steps can help to improve sublimation rates and / or decrease intra-batch heterogeneity, depending on the particular conditions and composition.
    [00070] In some modality, an annealing step is optional.
    [00071] In other embodiments, after the second period of time, the second composition is exposed to a third temperature for a third period of time, in which the third temperature is below the second temperature. For example, in some embodiments, the third temperature is about the same as the first temperature. In other embodiments, the third temperature is at least 5 ° C below the second temperature, illustratively, about 5 ° C to about 30 ° C and about 10 ° C to about 20 ° C below the second temperature. For example, where the second temperature is about -30 ° C, in some embodiments, the second temperature is about -50 ° C.
    [00072] In some embodiments, the present invention provides a method of lyophilizing a composition comprising at least one active ingredient and at least one crystallization excipient. The method comprises:
    (a) exposing the composition to a first temperature for a first period of time sufficient to obtain a first composition having at least one crystallization excipient partially or completely crystallized; (b) exposing the first composition to a second temperature for a second period of time to obtain a second composition, wherein the second temperature is above the first temperature; and (c) exposing the second composition to a third temperature for a third period of time to obtain a third composition, wherein the third temperature is below the second temperature.
    [00073] In one embodiment, the time period is at least about 30 minutes, illustratively, about 30 minutes to about 20 hours, about 1 to about 18 hours, about 2 to about 16 hours, about from 3 to about 14 hours, about 4 to about 10 hours, about 5 to about 8 hours, and about 6 to about 7 hours. In another mode, the time period is about 6 hours. In other modalities, the time period is about 3 hours. In other embodiments, the third time period is less than, greater than or about equal to the first time period. In still other embodiments, the conditions (for example, temperature and time) in steps (a) and (b) are the same or substantially the same. C. Drying
    [00074] In other embodiments, the methods of the present invention further comprise a drying step. The drying phase can comprise a primary drying phase and a secondary drying phase.
    [00075] Consequently, in some embodiments, the present invention provides a method for lyophilizing a composition comprising at least one active ingredient and at least one crystallization excipient. The method comprises:
    (a) exposing the composition to a first temperature for a first period of time sufficient to obtain a first composition having at least one crystallization excipient partially or completely crystallized; and (b) drying the first composition to form a bololyophilizate.
    [00076] In other embodiments, the present invention provides a method for lyophilizing a composition comprising at least one active ingredient and at least one crystallization excipient, the method comprising:
    (a) exposing the composition to a first temperature for a first period of time sufficient to obtain a first composition having at least one crystallization excipient partially or completely crystallized; (b) exposing the first composition to a second temperature for a second period of time to obtain a second composition, wherein the second temperature is above the first temperature; (c) exposing the second composition to a third temperature for a third period of time to obtain a third composition, wherein the third temperature is below the second temperature; and (d) drying the third composition to form a lyophilized cake.
    [00077] In one embodiment, drying comprises a primary drying step. Primary drying can remove frozen water (ice sublimation). Preferably, unbound or easily removable ice is removed from the sample through primary drying. The unbound water at the beginning of the primary drying step can preferably be in the form of free ice, which can be removed by sublimation, that is, by converting it directly from a solid to a vapor.
    [00078] In some, the primary drying step can be conducted at a temperature of about -35 ° C to about 20 ° C or about -25 ° C to about 10 ° C or about -20 ° C at about 0 ° C. In one embodiment, the primary drying step is carried out at about 0 ° C. In other embodiments, the primary drying step can be carried out for a total time of at least about 1 hour, illustratively, about 1 hour to about 1 week, about 10 hours to about 4 days and about 20 hours about 40 hours. In another embodiment, the primary drying step comprises drying the first or third composition under a pressure of about 0 to about 200 mTorr (200 mm hg), preferably about 100 mTorr (100 mm hg), at a temperature of about -50 ° C for about 1 hour, followed by 0 ° C for about 35 hours.
    [00079] An optional "primary drying step" step (i.e., the temperature rise from the step prior to primary drying to the primary drying temperature) can be performed, according to the methods of the present invention, at a rate from about 0.1 ° C to about 10 ° C per minute.
    [00080] The primary drying step can be carried out long enough to ensure that substantially all frozen water is removed from the sample. Those skilled in the field will understand that the primary drying time varies with the configuration, as the primary drying duration may depend on the filling volume and geometry (resistance surface area / cake flow). In one embodiment, the primary drying duration is at least about 5 hours, illustratively, about 5 hours to about 100 hours, about 10 hours to about 80 hours, about 30 hours to about 60 hours and about from 40 to about 50 hours.
    [00081] Primary drying can be monitored using any of a number of methods, including observing changes in product temperature during lyophilization. Another method is to observe changes in the pressure in the chamber where, when sublimation ends, no more water molecules in the chamber contribute to changes in pressure. The end of the primary drying step can be determined to be when the temperature of the product (sample) approaches the temperature of the shelf, for example, evidenced by a significant change in the decline in the temperature trace of the product due to a sublimation rate reduced; when sublimation ends, evaporative cooling ends. To prevent premature termination, in some modalities, an additional 2-3 hours of primary drying can be added to the duration. Another method for monitoring the end of primary drying is the pressure rise test where, disconnecting the vacuum source, the chamber pressure will rise at a rate depending on the amount of moisture in the product. In one embodiment, the end of the primary drying process can be configured as when the pressure rise rate is below a specified value. Another method for determining the end of the primary drying step is to measure the heat transfer rate.
    [00082] In other embodiments, directly before primary drying, the composition can be placed under vacuum at the stage temperature directly before primary drying. Once started, the vacuum can be present for the rest of the lyophilization process, although the vacuum level can change.
    [00083] Additional information on drying during lyophilization can be found in Carpenter, J. F. and Chang, B. S., Lyophilization of Protein Pharmaceuticals, Biotechnology and Biopharmaceutical Manufacturing, Processing and Preservation, K. E. Avis and V. L. Wu, eds. (Buffalo Grove, IL Interpharm Press, Inc.) (1996), which is incorporated here by reference for its teaching on drying.
    [00084] In one embodiment, drying still comprises one or more secondary drying steps to reduce moisture levels, preferably to levels that give a desired biological and / or structural character to the final product.
    [00085] In some embodiments, each of the one or more secondary drying steps is conducted at a temperature that is about 0 ° C or above, illustratively, about 0 ° C to about 100 ° C, about 10 ° C to about 90 ° C, about 20 ° C to about 80 ° C, about 30 ° C to about 70 ° C, about 40 ° C to about 60 ° C and about 45 ° C to about 50 ° C. In one embodiment, the secondary drying step comprises a first, a second and a third secondary drying step carried out at about 40 ° C, about 45 ° C and about 50 ° C, respectively. In one embodiment, the secondary drying step comprises a temperature of about 35 ° C over a period of time of about 16 hours.
    [00086] The step of raising the temperature in one or more secondary drying steps is here referred to as the "secondary drying step", which may be optional. Secondary drying elevation can be performed at a temperature rise rate of about 0.1 ° C to about 10 ° C per minute.
    [00087] Each of the one or more secondary drying steps can be carried out long enough to reduce the level of residual moisture in the lyophilized product to a final level. In some embodiments, the final residual moisture level is about 10% or less, illustratively, about 9% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, about 4% or less, about 3% or less, about 2% or less, about 1% or less, about 0.8% or less, about 0.6% or less , about 0.5% or less, about 0.2% or less and about 0.1% or less.
    [00088] In one embodiment, the secondary drying step is carried out at about 35 ° C. In other embodiments, the secondary drying step can be carried out for a total time of at least about 1 hour, illustratively, about 1 hour to about 1 week, about 10 hours to about 4 days and about 16 hours about 40 hours. In another embodiment, the secondary drying step comprises drying under a pressure of about 0 to about 200 mTorr (200 mm hg), preferably about 100 mTorr (100 mm hg), at a temperature of about 35 ° C for about 16 hours.
    [00089] To determine the level of residual moisture in a sample, the Karl Fischer method can be used, for example. In addition, the pressure rise test or the measurement of the heat transfer rate can also be used to determine the end of each of the one or more secondary drying steps. Alternatively, an electronic hygrometer or a residual gas analyzer can also be used. Also, the minimum duration of one or more secondary drying steps can be determined using different combinations of shelf temperatures (where the shelf temperature of one or more secondary drying steps is the same or less than the temperature used in the drying step. high temperature) and durations. The residual moisture content can be determined using several methods, including loss-when-drying, Karl Fischer titration, thermal gravimetric analysis (Thermal Gravimetric Analysis - TGA), gas chromatography (Gas Chromatography - GC) or infrared spectroscopy .
    [00090] Without being bound by any particular theory, it is believed that, during lyophilization, the active ingredient is converted from an aqueous phase to an amorphous solid phase, which is believed to protect the active ingredient against chemical instability and / or conformational. The lyophilized preparation not only contains an amorphous phase, but also includes a component that crystallizes during lyophilization. This can provide lyophilization of the active ingredient and the formation of a more elegant cake (for example, a cake with minimal retraction from the sides of the container in which it was lyophilized).
    [00091] In one embodiment, the lyophilized cake is characterized as being less than 50% fragmented. In another embodiment, the lyophilized cake is characterized as being about 0% to about 24% fragmented.
    [00092] In another aspect, the present invention provides a method of lyophilizing an aqueous pharmaceutical formulation comprising AT III, the method comprising:
    (a) exposing the formulation to a temperature below about -45 ° C for a period of time sufficient to obtain a first composition having at least one partially or completely crystallized excipient of crystallization; and (b) drying the first composition to form a lyophilized cake.
    [00093] In other respects, the present invention provides a method of lyophilizing an aqueous pharmaceutical formulation comprising AT III, the method comprising:
    (a) exposing the formulation to a freezing temperature below about -50 ° C for a period of time sufficient to obtain a first composition having at least one crystallization excipient partially or completely crystallized; and (b) drying the first composition to form a lyophilized cake.
    [00094] In some embodiments, the method optionally further comprises an annealing step, in which the formulation is exposed to an annealing temperature that is above the freezing temperature.
    [00095] In another aspect, the present invention provides a method of lyophilizing an aqueous pharmaceutical formulation comprising AT III, the method comprising:
    (a) exposing the formulation to a temperature below about -60 ° C for a period of time sufficient to obtain a first composition having at least one crystallization excipient partially or completely crystallized; and (b) drying the first composition to form a lyophilized cake.
    [00096] Also provided are compositions (for example, crystallized and / or lyophilized cakes and pharmaceutical compositions) prepared according to the methods of the present invention.
    [00097] Consequently, in some embodiments, the present invention provides a lyophilized AT III composition or cake prepared in accordance with the present invention.
    [00098] In other embodiments, the methods of the present invention provide products that at least maintain or substantially maintain the potency of the active ingredient (s) after storage of the lyophilized product. In one embodiment, the potency of the active ingredient (s) is maintained or substantially maintained after storage of the lyophilized product at about 5 ° C, about 25 ° C or about 40 ° C for about about 1, about 2, about 3 or about 6 or more months. In another modality, after storage of the lyophilized product, the potency of the active ingredient is at least about: 70%, 80%, 90%, 95%, 99% and 100% with respect to its pre-lyophilization potency. Kits
    [00099] In still other aspects, also provided are kits comprising the pharmaceutical compositions of the present invention, in which the kit still comprises a dry and a liquid component, in which the dry and liquid components can be present in separate containers in the kit or some of the components can be combined in one container, such as a kit in which dry components are present in a first container and liquid components are present in a second container, where the containers may or may not be present in a combined configuration. Optionally, the kits can also comprise a series of additional reagents. Optionally, the kits can also include instructions for using the kit components including, for example, instructions for reconstituting the lyophilized composition with an appropriate diluent. The instructions may be present in the kits as a package insert, on the label of the kit container or components thereof.
    [000100] The present invention will be illustrated in more detail by way of Examples, but it should be noted that the invention is not limited to the Examples. EXAMPLES Example 1
    [000101] To determine the freezing conditions that promote the crystallization of components in an AT III solution and to improve the physical appearance of the final product, lyophilization was performed on AT III formulations containing human plasma-derived AT III (6.88 mg / ml), alanine (100 mM) and NaCI (150 mM). Alanine and NaCI are crystalline excipients. For this formulation, the physical appearance can be directly related to the crystallinity of the excipients. It was desirable to crystallize NaCI and alanine as completely as possible during freezing in order to provide a solid matrix to support the cake structure.
    [000102] Differential Scanning Calorimetry: Freeze-thaw thermal events of the AT III formulation were investigated with a differential scan calorimeter (Model 2920, TA Instruments, Inc., New Castle, DE). The DSC temperature and cell constant were calibrated according to the standard procedure using high purity indium. Modulated DSC was used to study the heat flow and change in thermal capacity (Cp) of the maximally frozen concentrated solutes. The operations were performed with an amplitude of 0.5 ° C over a period of 80 sec. The sample, of 20 microliters, was sealed in an airtight aluminum pan and scanned through a subzero temperature range.
    [000103] Thermal events in NaCI, Alanine and AT III reconstituted solution: Crystallization and fusion events were investigated in a NaCI, alanine and AT III reconstituted solution.
    [000104] Experimental DSC Design by E-CHIP: A DOE designed by Echip was performed to evaluate the effects of freezing temperature, freezing maintenance time and ring maintenance time on the crystallization of excipients. The freeze lift rate (from 5 ° C to the freezing temperature) was set to 2 ° C / min. After annealing, the product was frozen at -30 ° C to the freezing temperature at 5 ° C / min. The rate of rise in heating was fixed as rc / min.
    [000105] The effect of elevation rates on crystallization: Different cooling rates (2 ° C / min vs. 0.2 ° C / min) were compared to investigate the effect of elevation rates on crystallization. Various rates of elevation during annealing (5 ° C / min vs. 0.2 ° C / min, rc / min vs. 0.2 ° C / min) were also assessed.
    [000106] The formation of a condensed phase: During the supercooling process, molecular conformations and configurations that were available in the liquid phase, but not in a crystalline solid phase, are frozen. This process of "retention" of conformations and configurations during cooling occurs when the rate of increase in viscosity exceeds the rate of molecular reorientation. The "freezing" in conformational states results in a condensed phase that will have some degree of molecular short-range magnitude, but, similar to the liquid, it will lack the characteristics of long-range magnitude of a solid crystalline PI.
    [000107] The formation of the condensed phase was observed through modulated DSC, where the thermal capacity (Cp) of the frozen concentrated amorphous phase decreased continuously until equilibrium was reached. Cp is an intrinsic property and is directly related to molecular mobility. The higher the Cp, the more mobility and a lower Cp indicates less mobility. A liquid material has a higher Cp than its solid counterpart. The decrease in Cp is due to the physical transformation of a material from a more fluid state to a solid state.
    [000108] Cp was monitored using the freezing and annealing protocol shown in Table 1. Table 1: AT III lyophilization cycle for first operation
    [000109] The solution was frozen from 0 to -52 ° C and kept for 120 min. It was then heated to -30 ° C and maintained for 1 hour. Finally, the product was frozen again at -52 ° C for a further 2 hours and then raised to 0 ° C. The first freezing rate was 0.2 ° C / min. The effect of freezing maintenance time (2 hours, 5 hours and 10 hours) and temperature (-46 ° C, -48 ° C and -52 ° C) on Cp was also evaluated.
    [000110] Lyophilization: Most of the experiments were carried out on the Lyostar II FTS system (SP Industries). Some were conducted in the Minilyo freeze dryer (Usifroid). The freezing techniques are listed in Table 2. Table 2: Freezing technique Table 2: Freezing Technique
    [000111] Techniques 1 to 5 differ in terms of shelf temperature and maintenance time for the first freezing stage. The second freezing temperature was set to be the same as the first freezing temperature and the holding time for the first freezing stage. The second freezing temperature was set to the same as the first freezing temperature and the holding time for the second freezing was 2 hours. Technique 6 specifies the condition that the product was frozen at -52 ° C for 2 hours, annealed at -30 ° C for 1 hour and frozen again to -52 ° C for an additional 15 hours. Girdling, primary and secondary drying were the same for all cycles, as listed in Table 1.
    [000112] Scanning Electron Microscopy (SEM): An SEM (Hitachi, Model S-3200, NCSU) was used to examine the morphologies of lyophilized cakes. The sample images on the surfaces or below the surfaces were viewed at a magnification of 50 to 5000 times. Due to the fact that lyophilized cakes are good thermal insulators, they charged when exposed to the electron beam. This resulted in loss of resolution. To reduce the effects of loading when exposing samples to the electric beam, all samples were coated with a thin layer of gold by electroplating using a bench Denton Vacuum. Images of a fragmented cake, a solid cake, NaCI crystal and alanine crystal were taken.
    [000113] X-ray powder diffraction: X-ray powder diffraction (XRD) has been applied to characterize the crystallinity of a fragmented cake (ETP 5807) and a solid cake (ETP 5807 26N9540) . XRD patterns were recorded using a diffractometer (Rigaku, model Multiflex) with copper Ka radiation at 40 kV and 40 mA. The scans were conducted in the range 20 from 10 ° to 90 °. The scanning speed was 17 minutes for the NaCI sample and 0.1257 minutes for alanine, ETP 5807. Results and discussion:
    [000114] DSC work was aimed at characterizing the critical factors that guide the crystallization properties of excipients in the formulation of AT III. The crystallization temperature (Tx), eutectic melting temperature (Te) and percentage crystallization were determined.
    [000115] Crystallization and fusion of NaCI, alanine and AT III solution: For the pure NaCI solution, the exothermic crystallization peak occurred at approximately -38 ° C during freezing and the endothermic melting peak appeared at -19 ° C during heating (figure 1). The melting heat for the melting peak was determined to be 7.4 J / g. The thermogram for the alanine solution showed an exothermic peak at -45 ° C during freezing, indicating crystallization. During heating, however, there was a group of small peaks occurring at approximately -44 ° C. The origin of these peaks was difficult to determine (figure 2).
    [000116] When the reconstituted AT III solution was analyzed, there was no evidence of exothermic activity observed during freezing. However, a peak of eutectic fusion was observed at -22 ° C, most likely due to NaCI (figure 3). The heat of fusion (2.0 J / g) was lower than the pure NaCI solution. The reduction in the heat of fusion could be attributed to the partial crystallization of NaCI in the formulation of AT III. Based on this correlation, the percentage crystallization was calculated by dividing the heat of fusion obtained from the formulations by a constant of 7.4 J / g, which is the heat of fusion for the pure NaCI solution.
    [000117] DOE Results: A DOE designed by ECHIP using the central composite cube model was performed to evaluate the effects of freezing temperature, freezing maintenance time and ring maintenance time on the crystallization of the AT III solution ( Table 3). Table 3: Crystallization profile

    [000118] The DOE results indicated that all the variable conditions evaluated had a significant impact on the crystallization of the solution. Freezing at -52 ° C produced a higher percentage of crystalline NaCI when compared to freezing at temperatures of -44 ° C and -60 ° C. The decrease in crystallization at a lower temperature (-60 ° C) can be explained by a balance between crystallinity and the rate of crystallization. The crystallinity was higher at a lower temperature. However, the solution was so viscous that the rate of crystallization was significantly reduced. Analysis of DOE data provided an optimum freezing temperature at -54 ° C (figure 4).
    [000119] An evaluation of the maintenance times indicates that the prolongation of the freezing maintenance time and the annealing maintenance time gives an increase in the percentage of crystallization. DOE results suggest that the optimum maintenance time is 10 hours for freezing and annealing (figure 4).
    [000120] Data analysis also provides an "out-of-fit" message, indicating that the model generated by E-CHIP might not fully reflect the crystallization process. Therefore, additional DSC work was carried out to better understand the change in physical property accompanied by the crystallization process during freezing and annealing.
    [000121] The effect of the elevation rate on crystallization: As a plasticizer, water acts as a physical diluent that increases free volume and molecular mobility. It is the ability of water to increase molecular mobility that can promote processes controlled by diffusion, such as crystallization. Rapid cooling retains more water within the amorphous phase, while slow cooling allows water to flow from the system. Consequently, rapid cooling promotes the formation of crystals. When the freezing rate was reduced from 2 ° C / min to 0.2 ° C / min, the percentage crystallization of NaCI was decreased by 82% (from 17% to 3%).
    [000122] Rate of elevation during annealing: When elevation of freezing to a warmer temperature, molecular mobility is increased to a point such that nucleation and crystallization occur. The rate of elevation at this stage should be slow enough to produce enough crystals. The decrease in the rate of elevation from 1 ° C to 0.2 ° C / min increased the percentage crystallization from 38% to 95%. Further decrease in the elevation rate to 0.1 ° C / min does not show much difference.
    [000123] When raised from -30 ° C to -52 ° C, the decrease in the rate from 5 ° C / min to 0.2 ° C / min increased crystallization 1.35 times (from 17% to 39%). These results suggest that the elevation rate of 0.2 ° C / min was appropriate for crystallization to occur.
    [000124] Condensed and crystallized phase: Additional work was focused on the condensed and crystallized phase. Figure 5A shows the change in Cp over time through the ETP-5807 cycle (Table 1). There was little change in Cp during the first freeze (figure 5B), annealing (figure 5C) and second freeze (figure 5D). The formation of the condensed phase is demonstrated by the drop in Cp. Little change in Cp indicates that little phase change occurs during freezing and annealing. Using these parameters, only 75% crystallization was obtained. The percentage crystallization was calculated by dividing the heat of fusion, which is 5.5 J / g (figure 6), by the constant 7.4 J / g, which is the heat of fusion for the pure NaCI solution.
    [000125] The formation of the condensed phase is observed with the prolongation of the freezing maintenance time. Figure 7A shows the entire picture of Cp change during freezing and annealing. When the first freezing maintenance time was extended from 2 hours to 5 hours, the Cp dropped to a minimum equilibrium value, indicating the change from a more fluid phase to a more condensed phase (figure 7B). Additional increase in maintenance time from 5 hours to 10 hours does not illustrate an additional decrease in Cp (data not shown). A crystallization peak was observed during the heating rise (figure 7C). This single peak was not present when the freezing maintenance time was just 2 hours. If the solution crystallized completely during the first freeze and heat rise, it can be speculated that additional freezing or annealing would have little or no effect on Cp. This was demonstrated by the fact that no changes in Cp were observed during annealing and second freezing (figures 7D and 7E). The percentage crystallization was increased to 87% when the freezing maintenance time was extended from 2 hours to 5 hours. Again, the percentage crystallization was calculated by dividing the heat of fusion, which is 6.4 J / g (figure 8) by the constant of 7.4 J / g.
    [000126] These results indicate that 5 hours at -52 ° C are required for the amorphous phase of AT III to complete the physical transformation. The condensed phase begins to form only by freezing for only 2 hours. Sufficient freezing maintenance time is a prerequisite for crystallization.
    [000127] Similar work was carried out at temperatures warmer than -52 ° C. These results indicate no crystallization activity when the product temperature was - 46 ° C. At a temperature of -48 ° C, when the maintenance time increased from 4 hours to 5 hours, the percentage crystallization increased from 36% to 84%. Therefore, it is preferable that the AT III solution is frozen below -48 ° C for at least 5 hours in order to induce sufficient crystallization.
    [000128] Development of the lyophilization process: In order to confirm the results of DSC work on a macroscopic scale, four freezing temperatures (-50 ° C, -52 ° C, -54 ° C and -60 ° C) and two Maintenance times (2 hours and 6 hours) were evaluated in a laboratory freeze dryer.
    [000129] Freezing at -52 ° C for 2 hours: An initial assessment of the current cycle parameters in Table 1 used during the run was performed using the Lyostar II FTS unit. The temperature and pressure profile in the chamber is shown in figure 9. The product's hottest temperature, measured by thermocouplers during the freezing process, was approximately -49 ° C (figure 10). After processing, the physical examination revealed that only 2% of the cakes were acceptable, 17% had small holes, 57% were partially fragmented and 23% were broken. Based on the DSC results, the product temperature (-49 ° C) was cold enough to induce crystallization, however, the freezing maintenance time needs to be at least 5 hours to form the condensed phase before crystallization. The freezing duration of 2 hours was too short to provide enough crystals.
    [000130] Freezing at -54 ° C for 2 hours: In this cycle, AT III solution was frozen at -54 ° C for 2 hours, annealed at -30 ° C for 1 hour and frozen again at -54 ° C for 2 hours. hours. Freezing was done on the Lyostar II FTS unit. Primary and secondary drying were carried out on CS10-0.5 (Serail 14L03). The graphs in figures 11 & 12 showed that the product temperatures were kept below -50 ° C during freezing. Physical inspection revealed that 74% of the cakes were acceptable and 26% had small holes. Even though we observed the improvement in the appearance of the cake by reducing the product temperature from -49 ° C to -50 ° C, the result is still not satisfactory. These results indicate that freezing at low temperature alone is not enough to induce complete crystallization.
    [000131] Freezing at -54 ° C for 6 hours: In this cycle, AT III solution was frozen at -54 ° C for 6 hours, annealed at -30 ° C for 1 hour and frozen again at -54 ° C for 2 hours. hours. The cycle was operated in an FTS lyophilization unit. The product temperatures were kept below -50 ° C during freezing (figures 13 & 14). The physical examination indicated that all cakes were acceptable. These results indicate that the product temperature and the freezing maintenance time are equally important to ensure optimum crystallization. This result is consistent with DSC observation.
    [000132] Freezing at -50 ° C for 6 hours: In this cycle, AT III solution was frozen at -50 ° C for 6 hours, annealed at -30 ° C for 1 hour and frozen again at -50 ° C for 2 hours. hours. The cycle was operated on the Lyostar II FTS unit. Using these parameters, the product temperatures were kept below -47 ° C and above -48 ° C during freezing (figures 15 & 16). Physical inspection indicated that only 18% were acceptable, 23% had small holes and 59% exhibited fragmentation. This study confirms the previous discovery by DSC that the temperature of the product needs to be below -48 ° C in order to initiate crystallization. It also demonstrates that prolonging the freezing maintenance time alone is not enough to form enough crystals.
    [000133] Freezing at -60 ° C for 6 hours: In this cycle, AT III solution was frozen at -60 ° C for 6 hours, annealed at -30 ° C for 1 hour and frozen again at -60 ° C for 2 hours. The cycle was operated on the Minilyo freeze dryer (Usifroid). The product temperature was -51.6 ° C on the top shelf and - 52.7 ° C on the bottom shelf during freezing (figures 17 & 18). The physical examination indicated that all cakes were acceptable. This experiment further demonstrates that decreasing the shelf temperature and prolonging the maintenance time are important strategies for producing pharmaceutically acceptable cakes.
    [000134] Freezing at -52 ° C for 15 hours: In this cycle, AT III solution was frozen at -52 ° C for 2 hours, annealed at -30 ° C for 1 hour and frozen again at -52 ° C for 15 hours. hours. Freezing was done on the Lyostar II FTS unit. Primary and secondary drying were carried out on the Serail due to the fact that the isolation valve on the FTS was closed during the primary drying. The hottest product temperatures, measured by thermocouples during freezing, were below -48 ° C (figures 19 & 20). The physical appearance of all the cakes was acceptable. Based on the DSC results, -48 ° C is the hottest product temperature required to induce crystallization and a maintenance time of 15 hours appears to be long enough to ensure complete crystallization.
    [000135] Summary: Table 4 lists the temperature response to different shelf temperature setpoints. Table 4: Temperature response to different shelf temperature setpoints
    A = Dryer; B = Shelf temperature setpoint (° C); C = Shelf inlet (° C); D = Exit from the shelf (° C); E = Top shelf entrance (° C); F = Exit from the upper shelf (° C); G = Bottom shelf entry (° C); H = Output from the lower shelf (° C); and I = Temp, of product (° C).
    [000136] Since the product temperature is typically 4 ° to 6 ° C warmer than the shelf temperature set point, the target shelf temperature is preferably set to -54 ° C to ensure that all product temperatures remain below -48 ° C throughout the freeze dryer. Based on the results of these studies (Table 5), the temperature of the target shelf during freezing can be selected to ensure that product temperatures are well below -48 ° C. Table 5. Effect of freezing temperature and maintenance time on the appearance of the cake
    * small holes; **fragmented; ***broke.
    [000137] In addition, sufficient time may be allowed to ensure complete crystallization. The data indicate that a shelf temperature of -54 ° C, with a soak of 6 hours, can achieve these conditions and promote adequate crystallization. Therefore, an extension of the freezing soak time from 2 hours to 6 hours, and a decrease in the target shelf temperature set point, from -52 to -54 ° C, would improve the physical appearance of the final product.
    [000138] Freeze-dried cake morphology: The freeze-dried cake morphology was observed through a scanning electron microscope. A partially fragmented cake was used as a control for the solid and strong cake. The fragmented cake contains many flakes that are thin and porous (figure 21 A). A solid cake (figure 21B) is composed mainly of plate-shaped crystals, with a few round crystals distributed across the cake. NaCI itself forms small round crystals (figure 22). Alanine only (figure 23) forms continuous plates with a few holes, probably resulting from ice sublimation. It could be inferred that the plate-shaped crystals in Figure 21B are primarily of alanine and the round-shaped crystals of NaCI.
    [000139] X-ray powder diffraction: Based on data generated from DSC and freezing studies, a second operation at full load of ETP-5807 was performed. This operation incorporated a lower freezing temperature during the first freezing step, as well as a longer soak time. The modified cycle produced a product with an acceptable physical appearance.
    [000140] In order to characterize the crystallinity of a fragmented cake from the first operation and a solid cake from the second operation, the XRD standards of NaCI, alanine, ETP 5807 (fragmented cake) and material from the second operation of ETP 5807 (solid cake ) were evaluated (figure 24). The main peaks of crystalline diffraction of NaCI are at 31.7 ° and 45.5 ° 20. The main peak of crystalline diffraction of alanine is at 20.5 ° 20. A wide peak that occurs in samples of alanine is attributed to the portion amorphous. Cakes of ETP 5807 (1st operation) and ETP 5807 (2nd operation) show the combination of peak NaCI and alanine. A wide peak is also observed for both samples.
    [000141] Crystallinity is calculated by dividing the crystalline peak area by the sum of the crystalline and amorphous peak area. The crystallinities of NaCI, alanine, ETP 5807 and ETP 5807 (2nd operation) are, respectively, adapted to be 99 ± 20%, 50 ± 1%, 66 ± 2% and 60 ± 1%. No difference in the diffraction pattern is noted for the fragmented cake and the solid cake.
    [000142] Conclusions: The AT III formulation was characterized with an emphasis on percentage crystallization for the freeze-drying protocol design. The results indicate that freezing temperature and maintenance time are equally important prerequisites for complete crystallization. In some embodiments, lyophilization may comprise a freezing temperature of about -54 ° C, as well as an extended soak time of about 6 hours. The tests provided pharmaceutically acceptable end products. Example 2
    [000143] Thirty ml vials were filled with ten milliliters of sterile filtered solution comprising AT III (-6.88 mg / ml), alanine (100 mM (-8.91 mg / ml)) and NaCI (150 mM, ( -8.7 mg / ml)). AT III samples were first frozen to -25 ° C, kept for 2 hours and then still frozen to -54 ° C, followed by maintenance for 6 hours. The shelf temperature was then slowly raised to -30 ° C at a rate of 0.2 ° C / min and maintained at that temperature for 2 hours and then slowly lowered to 0.2 ° C / min back to -54 ° C. The products were kept at -54 ° C for 2 hours before starting primary drying. Primary drying was carried out at a shelf temperature of 0 ° C and a controlled chamber pressure of 100 mTorr (100 mm hg). Primary drying lasted approximately 32 hours before the start of secondary drying. Secondary drying was carried out at a shelf temperature of 35 ° C and a chamber pressure of 100 mTorr (100 mm hg) for 14 hours.
    [000144] After drying, about 100% of the pharmaceutically acceptable lyophilized cake resulted. The percentage of pharmaceutically acceptable cake was calculated by dividing the quantity of cake acceptable by the number of cakes in the whole batch. In addition, modulated DSC was applied and the formation of a condensed phase during the freezing stage and the crystallization process during the heating rise was observed.
    权利要求:
    Claims (15)
    [0001]
    Lyophilization method of a composition comprising antithrombin-II (AT III) and at least one crystallization excipient selected from the group consisting of alanine, mannitol, glycine and NaCI, the method characterized by the fact that it comprises:
    (a) exposing the composition to a first temperature of about -48 ° C or below
    (b) maintaining the temperature of the composition at about -48 ° C or below for a period of time from about 4 hours to about 10 hours before lyophilization to obtain a first composition having at least a partial crystallization excipient or completely crystallized.
    [0002]
    Method according to claim 1, characterized by the fact that the first temperature is about -54 ° C or below.
    [0003]
    Method according to claim 1, characterized by the fact that the first period of time is at least about 5 hours.
    [0004]
    Method according to claim 1, characterized by the fact that the at least one crystallization excipient is alanine and NaCl.
    [0005]
    Method according to claim 4, characterized by the fact that alanine and NaCI are present in the composition about 100 mM each.
    [0006]
    Method according to claim 1, characterized in that the first temperature and the first period of time are sufficient so that the at least one crystallization excipient is completely or almost completely crystallized.
    [0007]
    Method, according to claim 1, characterized by the fact that the composition still comprises one or more excipients, each selected from the group consisting of: a stabilizing agent, a buffering agent, a surfactant, an anti-oxidant and a divalent cation.
    [0008]
    Method according to claim 1, characterized in that the composition still comprises a buffer selected from the group consisting of: phosphate buffer, acetate buffer, citrate buffer and citric acid / phosphate buffer, histidine, tris- ( hydroxymethyl) -aminomethane, 1,3-bis- [tris- (hydroxymethyl) methylamino] - propane, histidine, piperazine-N, N'-bis- (2-ethanesulfonic acid), 3- (N-morpholino) propane-sulfonic acid, N-2-hydroxyethyl-piperazine-N'-2-ethane-sulfonic acid, 2- (N-morpholino) ethane-sulfonic acid and N-2-acetamido-2-aminoethane-sulfonic acid.
    [0009]
    Method according to claim 1, characterized by the fact that it still comprises drying the first composition to obtain a lyophilized cake.
    [0010]
    Method according to claim 1, characterized in that the lyophilized cake is a cake at least 50% solid.
    [0011]
    Method according to claim 1, characterized in that the composition is a liquid pharmaceutical composition comprising a pharmaceutically acceptable carrier.
    [0012]
    Method according to claim 1, characterized in that it further comprises exposing the first composition to a second temperature for a second period of time to obtain a second composition, wherein the second temperature is above the first temperature.
    [0013]
    Method according to claim 12, characterized in that it further comprises exposing the second composition to a third temperature for a third period of time to obtain a third composition, wherein the third temperature is below the second temperature.
    [0014]
    Method according to claim 13, characterized in that it further comprises drying the third composition to obtain a lyophilized cake.
    [0015]
    Freeze-drying method of a liquid composition comprising AT III derived from plasma, NaCI and alanine, characterized by the fact that it comprises:
    (a) exposing the composition to about -54 ° C or below, so that the temperature of the composition is about -48 ° C or below for about 5 hours or more, in order to provide a first composition having one or more components in it, completely or almost completely, crystallized; and
    (b) drying the first composition to obtain a lyophilized cake.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012012460B1|2020-06-23|Freeze-drying method of a composition
    JP6253627B2|2017-12-27|Novel factor VIII formulation not containing albumin
    Bhatnagar et al.2008|Study of the individual contributions of ice formation and freeze-concentration on isothermal stability of lactate dehydrogenase during freezing
    Liao et al.2007|Influence of processing conditions on the physical state of mannitol—implications in freeze-drying
    US20070196364A1|2007-08-23|Pharmaceutical Formulation and Process
    JP2007236975A|2007-09-20|Prepared substance for stabilizing biomaterial by unfreeze-drying process and method thereof
    KR20080106894A|2008-12-09|Method of inducing nucleation of a material
    Thorat et al.2019|Characterization of phosphate buffered saline | in frozen state and after freeze-drying
    RU2735082C2|2020-10-28|Method of producing lyophilized pellets containing a viii factor
    PT1968592E|2012-06-18|Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds and a disaccharide for treating proliferative diseases
    Dixon et al.2009|The impact of protein concentration on mannitol and sodium chloride crystallinity and polymorphism upon lyophilization
    Stärtzel et al.2016|Mannitol/l-arginine-based formulation systems for freeze drying of protein pharmaceuticals: effect of the l-arginine counter ion and formulation composition on the formulation properties and the physical state of mannitol
    Patel et al.2014|Differential effect of buffering agents on the crystallization of gemcitabine hydrochloride in frozen solutions
    Hirakura et al.2004|The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 |
    Izutsu et al.2014|Effects of formulation and process factors on the crystal structure of freeze-dried Myo-inositol
    JP2022509904A|2022-01-25|Freeze-dried treosulfan
    WO2020064816A1|2020-04-02|Solution comprising treosulfan
    Wang2004|Formulation characterization
    Nail2016|Stability considerations in development of freeze-dried pharmaceuticals
    Kochkalova et al.2011|Determining of Eutectic Temperature using the Methods of Electric Conductivity and Investigation of Thermal Parameters of Heterological Anti-Rabies Immunoglobulin by Differential Scanning Calorimetry
    同族专利:
    公开号 | 公开日
    RU2012126125A|2013-12-27|
    PT2503995T|2017-11-23|
    IL219827A|2016-12-29|
    ES2648249T3|2017-12-29|
    JP5810091B2|2015-11-11|
    NZ600271A|2013-09-27|
    CN102762196A|2012-10-31|
    IL219827D0|2012-07-31|
    CN102762196B|2014-05-14|
    EP2503995A4|2014-05-21|
    WO2011066291A3|2011-10-06|
    MX2012005782A|2012-08-03|
    CA2781120C|2015-01-27|
    US20130040890A1|2013-02-14|
    AU2010324839B2|2015-02-19|
    JP2015155455A|2015-08-27|
    ZA201203603B|2016-01-27|
    PL2503995T3|2018-01-31|
    US8648177B2|2014-02-11|
    WO2011066291A2|2011-06-03|
    AU2010324839A1|2012-06-14|
    BR112012012460A8|2018-07-03|
    RU2540480C2|2015-02-10|
    JP2013512194A|2013-04-11|
    CA2781120A1|2011-06-03|
    HUE037733T2|2018-09-28|
    BR112012012460A2|2017-10-10|
    WO2011066291A4|2011-12-22|
    KR101567901B1|2015-11-10|
    KR20120102715A|2012-09-18|
    EP2503995B1|2017-11-01|
    CL2012001350A1|2012-09-28|
    EP2503995A2|2012-10-03|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4087415A|1976-06-09|1978-05-02|William L. Wilson|Antithrombin III|
    JPS597693B2|1978-01-07|1984-02-20|Green Cross Corp|
    US4337242A|1980-02-05|1982-06-29|Merck & Co., Inc.|Vaccine stabilizer containing L-glutamic acid and L-arginine|
    DE3262575D1|1981-12-23|1985-04-18|Schering Corp|Stabilised interferon formulations and their preparation|
    US4632981A|1982-07-30|1986-12-30|Genentech, Inc.|Human antithrombin III|
    US4517294A|1982-03-03|1985-05-14|Genentech, Inc.|Human antithrombin III|
    US5218091A|1982-08-13|1993-06-08|Zymogenetics, Inc.|Glycolytic promoters for regulated protein expression: protease inhibitor|
    US4711848A|1984-03-14|1987-12-08|Zymogenetics, Inc.|Site specific mutagenesis in alpha-1-antitrypsin|
    US4931373A|1984-05-25|1990-06-05|Zymogenetics, Inc.|Stable DNA constructs for expression of α-1 antitrypsin|
    US4732973A|1984-06-14|1988-03-22|Chiron Corporation|Active site modified protease α-1-antitrypsin inhibitors|
    EP0169114B1|1984-06-19|1991-01-16|Transgene S.A.|Human alpha-1-antitrypin derivatives and process for their preparation|
    US5322775A|1986-06-30|1994-06-21|Pharmaceutical Proteins Ltd.|Peptide production|
    US4873316A|1987-06-23|1989-10-10|Biogen, Inc.|Isolation of exogenous recombinant proteins from the milk of transgenic mammals|
    DE3901917A1|1989-01-24|1990-07-26|Behringwerke Ag|MUTANTS OF HUMAN ANTITHROMBIN III|
    GB8913183D0|1989-06-08|1989-07-26|Central Blood Lab Authority|Chemical products|
    US5079336A|1989-06-23|1992-01-07|The Trustees Of The University Of Pennsylvania|α-1-antichymotrypsin, analogues and methods of production|
    US5032405A|1989-09-27|1991-07-16|Warner-Lambert Company|Oral pharmaceutical composition for acid sensitive proteinaceous agents|
    US5134119A|1990-10-16|1992-07-28|Lezdey John|Treatment of inflammation using 358 substituted alpha-antitrypsin|
    JP3479539B2|1992-04-10|2003-12-15|エーザイ株式会社|Human antithrombin III mutant|
    US5561115A|1994-08-10|1996-10-01|Bayer Corporation|Low temperature albumin fractionation using sodium caprylate as a partitioning agent|
    US5843705A|1995-02-21|1998-12-01|Genzyme Transgenic Corporation|Transgenically produced antithrombin III|
    AT405905B|1997-03-25|1999-12-27|Immuno Ag|NEW USE OF ANTITHROMBIN III|
    AT407114B|1997-06-10|2000-12-27|Immuno Ag|ALPHA 1-ANTITRYPSIN PREPARATION AND METHOD FOR THE PRODUCTION THEREOF|
    KR20010052345A|1998-05-12|2001-06-25|수잔 씨 복|Human antithrombin iiis and methods related thereto|
    DK1154796T3|1999-02-22|2007-09-24|Univ Connecticut|New albumin-free Factor VIII formulations|
    US20040157911A1|1999-08-31|2004-08-12|Spiridon Spireas|Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof|
    US20030170813A1|2000-07-05|2003-09-11|Kenichi Suga|Process for producing glycoprotein|
    US6432658B1|2000-09-13|2002-08-13|Affinity Biologicals, Inc.|Method for measuring antithrombin activity|
    AU2002335046A1|2001-10-19|2003-05-06|Inhale Therapeutic Systems, Inc.|The use of proton sequestering agents in drug formulations|
    AU2003223497A1|2002-04-05|2003-10-27|Centocor, Inc.|Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses|
    WO2003090682A2|2002-04-25|2003-11-06|The Scripps Research Institute|Treatment and prevention of pulmonary conditions|
    SI1664123T2|2003-09-22|2012-03-30|Kamada Ltd|Large scale preparation of alpha-1 proteinase inhibitor and use thereof|
    US7691810B2|2003-10-09|2010-04-06|Kyowa Hakko Kirin Co., Ltd|Method of producing recombinant antithrombin III composition|
    ES2375706T3|2003-11-14|2012-03-05|Baxter International Inc.|ALFA 1-ANTITRIPSIN COMPOSITIONS AND TREATMENT METHODS USING SUCH COMPOSITIONS.|
    US20050226893A1|2004-03-04|2005-10-13|Jennifer Juneau|Lyophilization method to improve excipient crystallization|
    JP2009516692A|2005-11-22|2009-04-23|ワイス|Immunoglobulin fusion protein preparation|
    DK1981572T3|2006-02-09|2013-03-04|Pari Pharma Gmbh|Pulmonary delivery of alpha-1 proteinase inhibitor|
    WO2008042408A2|2006-10-03|2008-04-10|Wyeth|Lyophilization methods and apparatuses|
    KR101567901B1|2009-11-24|2015-11-10|그리폴스 테라퓨틱스 인코포레이티드|Lyophilization methods, compositions, and kits|JP2013510158A|2009-11-03|2013-03-21|グリフオルス・セラピユーテイクス・インコーポレーテツド|Compositions, methods and kits for alpha-1 proteinase inhibitors|
    KR101567901B1|2009-11-24|2015-11-10|그리폴스 테라퓨틱스 인코포레이티드|Lyophilization methods, compositions, and kits|
    US10189773B2|2010-05-07|2019-01-29|Medicus Biosciences, Llc|In-vivo gelling pharmaceutical pre-formulation|
    US11083821B2|2011-08-10|2021-08-10|C.P. Medical Corporation|Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules|
    US10111985B2|2011-08-10|2018-10-30|Medicus Biosciences, Llc|Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules|
    WO2013170195A1|2012-05-11|2013-11-14|Medicus Biosciences, Llc|Biocompatible hydrogel treatments for retinal detachment|
    MY167579A|2012-08-16|2018-09-20|Pfizer|Glycoconjugation processes and compositions|
    WO2014113358A1|2013-01-15|2014-07-24|Teva Pharmaceutical Industries Ltd.|Lyophilization process|
    AU2014236385B2|2013-03-14|2019-01-24|C.P. Medical Corporation|Biocompatible hydrogel polymer matrix for delivery of cells|
    CN105309017B|2013-06-18|2019-12-31|Lg电子株式会社|Method for controlling transmission power in wireless communication system supporting change of usage of wireless resource and apparatus therefor|
    EP3065756B1|2013-11-07|2019-02-20|Dr. August Wolff GmbH & Co. KG Arzneimittel|Storage stable lyophilized tripeptide formulations|
    US10584371B2|2015-02-13|2020-03-10|Seegene, Inc.|Method for lyophilization of composition for multiple target nucleic acid sequence amplification reaction|
    CN104856965B|2015-05-29|2018-07-20|湖南科伦制药有限公司|A kind of freeze drying process of injection thymic peptide|
    US10966929B2|2015-09-07|2021-04-06|Mochida Pharmaceutical Co., Ltd.|Freeze-dried alginic acid preparation|
    TWI561783B|2015-10-29|2016-12-11|Tai Yiaeh Entpr Co Ltd|
    CN107677528A|2017-09-20|2018-02-09|上海贞元诊断用品科技有限公司|Calibration object and quality-control product of a kind of anticoagulant heparin detection reagent and preparation method thereof|
    CN107467013A|2017-09-20|2017-12-15|上海贞元诊断用品科技有限公司|Preparation method of quality control product universal plasma matrix capable of being stored for long time|
    法律状态:
    2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2018-06-26| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2019-12-03| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2019-12-17| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-05-05| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2020-06-23| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/11/2010, OBSERVADAS AS CONDICOES LEGAIS. |
    2021-09-14| B21F| Lapse acc. art. 78, item iv - on non-payment of the annual fees in time|Free format text: REFERENTE A 11A ANUIDADE. |
    2022-01-04| B24J| Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)|Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2645 DE 14-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
    优先权:
    申请号 | 申请日 | 专利标题
    US26401409P| true| 2009-11-24|2009-11-24|
    US61/264,014|2009-11-24|
    PCT/US2010/057816|WO2011066291A2|2009-11-24|2010-11-23|Lyophilization methods, compositions, and kits|
    [返回顶部]